Zomedica Corp.

Zomedica Corp. is a veterinary health company that specializes in developing products for companion animals. Founded in 2015 and headquartered in Ann Arbor, Michigan, the company focuses on solutions to the unmet needs of clinical veterinarians. Zomedica aims to provide solutions for diagnostics, treatments and monitoring for a wide range of diseases for cats, dogs and horses.

Their flagship product is the TRUFORMA platform, which provides point-of-care diagnostic products for disease states in dogs and cats. Specifically, it is used to detect and diagnose cancer in companion animals. The platform also offers PulseVet, a treatment solution for various musculoskeletal issues like broken bones, tendonitis, and torn ligaments in horses and small animals.

The company is currently collaborating with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals. The company is also working with Seraph Biosciences, Inc. to develop and markets a novel pathogen detection system.

Since its inception in 2015, the company has gone to be listed on the New York Stock Exchange (NYSE American) and is trading under the ticker symbol “ZOM”. In October 2020, the company changed its name from Zomedica Pharmaceuticals Corp. to Zomedica Corp., to better reflect the company’s focus on the veterinary health market.

The company is continuously investing in research and development and focusing on improving their products and technology. In 2020, the company initiated an employee donation campaign to support the wellness of pets through animal shelters and rescue organizations. This campaign resulted in a corporate contribution of total of $17,557 to Best Friends Animal Society, along with an additional $19,400 in supplies donated.